• Magazine
    • Past Issues
    • Subscribe
    • Change Mailing Address
    • Surveys
    • Guidelines for Authors
    • Editorial Calendar
    • Editorial Deadlines
  • Practice
    • Business Tips
    • Chiropractic Schools
    • Clinical & Technique
    • eBooks
    • eCourses
    • Infographics
    • Quizzes
    • Wellness & Nutrition
    • Personal Growth
    • Podcast
  • Resource Centers
  • Products & Services
    • Buyer’s Guide
    • Products Directory
    • Submit a Product
    • Vendor Login
  • Datebook
    • Become an Events Poster
    • Post an Event
    • View Events
  • Jobs
    • Jobs
    • Post a Job
  • Advertise
    • Advertising Information
    • Media Kit
    • Contact Us
    • Upload Advertising

Your Online Chiropractic Community

Chiropractic Economics Your Online Chiropractic Community
Subscribe
  • Home
  • Current Issue
  • News
  • Webinars
  • Chiropractic Research
  • Students
  • Coronavirus (COVID-19)

Theralase commences small animal pre-clinical trials for destruction of cancer cells

Chiropractic Economics November 13, 2010

November 13, 2010 — Theralase Technologies Inc. (TSX-V: TLT) has commenced the pre-clinical trial phase of its cancer research project; evaluating its patented Photo Dynamic Compounds (PDCs) in a small animal in-vivo model.

Lothar Lilge, PhD, the principal investigator of the PDCs and a researcher at the world renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network (UHN) will evaluate the toxicity of the patented PDCs on small animals, by choosing an escalating dose analysis.

Once completed, Lilge plans to demonstrate efficacy of the PDCs in the destruction of tumours in a small animal model.

Theralase first announced commencing small animal trials in June 2010. Testing can now proceed following receipt of approvals on its Animal Utilization Protocol by the UHN Ethics Review Committee.

“These small animal pre-clinical trials represent the next strategic step forward in our cancer therapy research program”, says Theralase President and CEO, Roger Dumoulin-White. “Now that approval has been granted, hands-on evaluation of the PDCs in a small animal model is able to commence full steam ahead. Successful completion of this milestone, will lay the groundwork for exploring the use of these PDCs in the destruction of cancers in larger animals, including: horses, cats, dogs and eventually humans.”

Lilge stated that, “Determination of the maximum tolerated dose is critical to providing us with safe PDC dosage levels that we can use to set recommended dosing guidelines to evaluate the efficacy of the PDCs in eradicating tumours in small animals while sparing normal tissue. Successfully destroying cancer in at least 2 animal models coupled with the completion of an OECD guideline toxicology analysis of the PDCs will be mandatory in setting the stage for future Phase 1 human clinical trials. We are currently investigating toxicity of four lead compounds in the safe and effective destruction of cancer cells in vivo. Due to the ability of these PDCs to work in low oxygen environments, these PDCs will be ideally suited in the destruction of solid core tumours, such as cancers of the breast, prostate, brain and lung.”

Source: Theralase, www.theralase.com

 

Related Posts

  • Theralase achieves success in destruction of listeria bacteriaTheralase achieves success in destruction of listeria bacteria
  • Theralase expands board of directors with strong financing capabilitiesTheralase expands board of directors with strong financing capabilities
  • Theralase photo dynamic compounds help destroy cancerTheralase photo dynamic compounds help destroy cancer
  • In vivo effects of low level laser therapy on inducible nitric oxide synthaseIn vivo effects of low level laser therapy on inducible nitric oxide synthase
  • Theralase study points to cancer breakthroughTheralase study points to cancer breakthrough
  • Theralase expands US sales force, appoints director of investor relationsTheralase expands US sales force, appoints director of investor relations

Filed Under: Industry News, News

Current Issue

Follow Us

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube logoYouTube logoYouTube

820 A1A N Highway W18,

Ponte Vedra Beach, FL 32082

Phone 904.285.6020

Fax 904.395.9118

CONTACT US »

Privacy Policy & Terms of Service

Copyright © 2021, All Rights Reserved

SUBSCRIBE TO THE MAGAZINE

Get Chiropractic Economics magazine
delivered to your home or office. Just
fill out our form to request your FREE
subscription for 20 issues a year,
including two annual Buyers Guides.

SUBSCRIBE NOW »

Latest Chiropractic News

  • Foot Levelers releases spring 2021 seminars schedule
  • MediHerb® introduces Ashwagandha Forte for patient sleep, stress, immunity support
  • HealthLight expands to include blue light therapy for chiropractors
x